A New Drug Target in Atherosclerosis: The Anaphylatoxin C5a, University of Vienna Study

Physorg.com -- For decades, doctors have looked at fitness levels, weight, and overall health risk factors for heart disease and stroke. Now, they may soon add a new risk factor to the list: activation of the complement system. The complement system is usually implicated in immune responses, but now there’s a role for it in cardiovascular disease. In a new research report appearing in the January 2011 print issue of the FASEB Journal, scientists from Europe and the United States show that anaphylatoxin C5a, a protein released when complement is activated, contributes to atherosclerotic disease. C5a causes plaques to break free from where they would be anchored to ultimately cause blockages elsewhere in the body. This new discovery not only shows that C5a is a new marker for identifying risk for heart attack and stroke, but it also establishes C5a as a new therapeutic target for preventing these problems.

MORE ON THIS TOPIC